MCL1 and acute myeloid leukemia: In AML 01-254-2014, the anti-leukemic effect of dual BCL-2/MCL1 targeting appeared more effective than a 5-day schedule of decitabine and comparable to the effect of decitabine in combination with BH3-mimetics targeting either BCL-2 or MCL1 (Fig. 5d).